Phenothiazines Enhance Macrophage Antibacterial Activity through ROS and Autophagy Induction

Study Background and Research Question

Bacterial infections remain a leading cause of mortality worldwide, with intracellular pathogens such as Salmonella enterica serovar Typhimurium, Shigella flexneri, Staphylococcus aureus, and Listeria monocytogenes posing particularly difficult therapeutic challenges. Traditional antibiotics often fail to eradicate these pathogens due to their ability to reside within host cells, evading direct drug action. This problem is further compounded by the rapid rise of antimicrobial resistance, prompting the search for new therapeutic strategies that are less likely to drive resistance or disrupt the host microbiome. Host-directed therapies (HDTs), which work by potentiating innate immune responses rather than directly targeting pathogens, have emerged as a promising paradigm. The reference study addressed a critical question: can phenothiazine compounds, widely recognized as neuropharmacological agents, enhance the antibacterial capacity of macrophages through modulation of host cell pathways?

Key Innovation from the Reference Study

The principal innovation of the study by Qiu et al. (Front. Immunol. 2025) lies in the detailed mechanistic elucidation of how phenothiazines, including perphenazine—a dopamine D2 receptor antagonist—can enhance macrophage antibacterial activity. The research demonstrates that these compounds induce both reactive oxygen species (ROS) production and autophagy in macrophages, two critical processes for the clearance of intracellular pathogens. Importantly, the study provides in vivo evidence that perphenazine treatment reduces organ inflammation and tissue lesions in a murine model of S. Typhimurium infection, connecting cellular mechanisms to physiological outcomes.

Methods and Experimental Design Insights

The research team employed a combination of in vitro and in vivo approaches to dissect the effects of phenothiazines on macrophage function. Key design elements included:

• Primary macrophage cultures treated with phenothiazine compounds, including perphenazine, to assess changes in lysosomal activity, autophagy, and ROS accumulation.
• Quantitative imaging and biochemical assays to measure autophagosome formation and ROS levels.
• Co-treatment with selective inhibitors: autophagy inhibitors (such as 3-methyladenine) and ROS scavengers (e.g., N-acetylcysteine) were used to dissect the relative contribution of each pathway to antibacterial activity.
• In vivo infection models in mice, specifically using S. Typhimurium, to evaluate the impact of perphenazine administration on infection severity, organ pathology, and inflammation.

This multifaceted approach allowed the authors to establish causative links between compound action, cellular pathways, and infection outcomes.

Core Findings and Why They Matter

The major findings are as follows:

• Phenothiazines elevate macrophage lysosomal activity: Treatment with these compounds increased the acidification and enzymatic function of lysosomes, which are central to pathogen degradation.
• Autophagy is robustly induced: Markers of autophagosome formation were upregulated, and autophagic flux increased, signifying that macrophages became more proficient at sequestering and degrading intracellular bacteria.
• ROS generation is enhanced: Phenothiazine-treated macrophages displayed elevated ROS levels, which are directly bactericidal.
• Dual requirement for ROS and autophagy: Pharmacological blockade of either pathway (using autophagy inhibitors or ROS scavengers) significantly suppressed the enhanced antibacterial effect, indicating both processes are required for maximal activity.
• In vivo efficacy: Perphenazine administration in infected mice led to reduced tissue damage and lower inflammatory burden, underscoring translational relevance.

These results collectively indicate that phenothiazines, via mechanisms distinct from their neuropharmacological roles, can potentiate the host's innate immune machinery. This is particularly significant for conditions where conventional antibiotics are limited by resistance or poor intracellular penetration. The findings also raise the potential for repositioning dopamine D2 receptor antagonist compounds as adjuncts in infection biology workflows.

Protocol Parameters

• Phenothiazine dosing in vitro: Treat primary macrophage cultures with 10-25 μM perphenazine for 24–48 hours to induce autophagy and ROS (see reference study and internal protocol).
• Inhibitor co-treatment: Use 3-methyladenine (5 mM) for autophagy inhibition and N-acetylcysteine (1–5 mM) for ROS scavenging to probe pathway specificity.
• In vivo administration: For murine models, administer perphenazine at doses titrated according to animal weight and infection severity, referencing prior dosing in host-pathogen studies.

Comparison with Existing Internal Articles

Several recent reviews and protocols corroborate and contextualize the reference study's findings. For instance, Perphenazine as a Dopamine D2 Receptor Antagonist: Advanced Research Uses highlights the dual neuropharmacological and immunomodulatory actions of perphenazine, reporting similar workflow recommendations for mitochondria-mediated cell death induction and anti-infective assays. Further, Perphenazine: Dopamine D2 Antagonist for Advanced Neuropharmacology expands on the utility of perphenazine in cellular immunity research, emphasizing its compatibility with autophagy and ROS-based readouts. These internal articles underline the translational and experimental flexibility of perphenazine, as both a dopamine receptor antagonist and a tool for host-pathogen interaction studies.

Limitations and Transferability

Despite compelling data, certain limitations must be considered:

• The specificity of phenothiazine effects may vary across cell types and species, necessitating careful titration and control selection in new experimental contexts.
• While in vivo efficacy was demonstrated in murine models of S. Typhimurium infection, extrapolation to other pathogens or clinical contexts requires further validation.
• Potential off-target effects related to the broad receptor binding profile of perphenazine (including α1-adrenergic and muscarinic receptors) could confound interpretation in complex physiological settings.

Thus, while the study lays a strong mechanistic foundation, researchers should critically assess transferability to their own model systems and infection types.

Why this cross-domain matters, maturity, and limitations

The bridging of neuropharmacology and immunology—exemplified by the use of dopamine D2 receptor antagonists like perphenazine for host-directed antibacterial strategies—opens new therapeutic and investigative pathways. This cross-domain approach is supported by mechanistic and in vivo evidence, but its maturity remains at the preclinical stage. Caution is warranted when extending these findings to other infection types or clinical applications, as further studies are needed to establish safety and efficacy in humans.

Research Support Resources

For laboratories seeking to replicate or extend these findings, Perphenazine (SKU B6157) from APExBIO is available for research use. This compound is well-characterized as a dopamine D2 receptor antagonist and supports both immunological and neuropharmacology research, including protocols for mitochondria-mediated cell death induction and host-pathogen interaction assays. Researchers are encouraged to consult the practical workflow recommendations for further guidance on assay design and compound handling.